ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 27 years Male

Specimen Collected: 5/1/2025 14:00 MDT

Keppra (Levetiracetam) |Received: 5/1/2025 14:01 MDT Report/Verified: 5/1/2025 14:01 MDT

Procedure	Result	Units	Reference Interval
Keppra (Levetiracetam)	**6.0** L i1	ug/mL	[10.0-40.0]

Test Information

i1: Keppra (Levetiracetam)

INTERPRETIVE INFORMATION: Keppra (Levetiracetam)

Therapeutic Range: 10-40 ug/mL
Toxic: Not well Established

Pharmacokinetics of levetiracetam are affected by renal function. Adverse effects may include somnolence, weakness, headache and vomiting.

This levetiracetam (Keppra) immunoassay uses the ARK Diagnostics reagents, which has known cross-reactivity with the drug brivaracetam (Briviact) and may report inaccurate results. Patients transitioning from levetiracetam to brivaracetam or those who are using both medications should not monitor drug concentrations with the ARK Diagnostics assay. These patients should be monitored using a validated chromatographic methodology that distinguishes between drugs to determine drug concentrations.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab